CryoPort (NASDAQ:CYRX) Stock Rating Reaffirmed by Needham & Company LLC

Share on StockTwits

CryoPort (NASDAQ:CYRX)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday, AnalystRatings.com reports. They presently have a $23.00 target price on the consumer goods maker’s stock. Needham & Company LLC’s price objective indicates a potential upside of 44.75% from the stock’s previous close.

Several other equities research analysts also recently weighed in on CYRX. ValuEngine downgraded shares of CryoPort from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. B. Riley decreased their target price on shares of CryoPort from $26.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Stephens began coverage on shares of CryoPort in a research report on Tuesday, January 7th. They set an “overweight” rating and a $21.00 target price for the company. Janney Montgomery Scott reissued a “buy” rating and set a target price on shares of CryoPort in a research report on Friday, March 6th. Finally, BidaskClub raised shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Friday, March 20th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $23.25.

NASDAQ CYRX traded up $0.36 during mid-day trading on Thursday, reaching $15.89. 34,959 shares of the stock were exchanged, compared to its average volume of 496,145. CryoPort has a one year low of $12.35 and a one year high of $25.02. The stock has a 50 day simple moving average of $17.15 and a 200-day simple moving average of $16.42. The stock has a market cap of $595.62 million, a P/E ratio of -29.63 and a beta of 0.81. The company has a debt-to-equity ratio of 0.03, a current ratio of 18.86 and a quick ratio of 18.77.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Thursday, March 5th. The consumer goods maker reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.04. CryoPort had a negative net margin of 54.01% and a negative return on equity of 19.08%. The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $9.20 million. During the same period in the previous year, the firm posted ($0.08) earnings per share. The business’s revenue was up 61.4% compared to the same quarter last year. Sell-side analysts anticipate that CryoPort will post -0.19 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. First Mercantile Trust Co. increased its holdings in shares of CryoPort by 19.8% in the 4th quarter. First Mercantile Trust Co. now owns 7,393 shares of the consumer goods maker’s stock worth $122,000 after buying an additional 1,221 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of CryoPort by 3.3% in the 4th quarter. Rhumbline Advisers now owns 39,816 shares of the consumer goods maker’s stock valued at $655,000 after purchasing an additional 1,273 shares in the last quarter. Barclays PLC boosted its stake in shares of CryoPort by 6.6% in the 4th quarter. Barclays PLC now owns 31,515 shares of the consumer goods maker’s stock valued at $519,000 after purchasing an additional 1,962 shares in the last quarter. Aigen Investment Management LP purchased a new stake in shares of CryoPort in the 4th quarter valued at $34,000. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of CryoPort in the 4th quarter valued at $41,000. 77.52% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Further Reading: Should You Consider an Index Fund?

Analyst Recommendations for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.